TNGX · Tango Therapeutics, Inc.
$23.34
-16.43% last session
End-of-day data · close of 2026-10-23
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-14.0
Dividend yield
0.0%
Beta
1.17
Avg volume
3M
Employees
0K
Daily Change %
-16.43%
5 Days Change
-0.81%
10 Days Change
5.18%
30 Days Change
-5.24%
60 Days Change
-5.77%
Month to Day Change
-4.54%
Year to Day Change
163.43%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TNGX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
JP Morgan
Overweight$46.00
+97.1% vs priceJefferies
Buy$60.00
+157.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-08-18 | HC Wainwright & Co. | Maintains | Buy | $66.00 → $68.00 |
| 2026-08-12 | Guggenheim | Maintains | Buy | $32.00 → $35.00 |
| 2026-07-17 | Mizuho | Maintains | Outperform | $36.00 → $40.00 |
| 2026-07-15 | JP Morgan | Initiates | Overweight | $0.00 → $46.00 |
| 2026-06-29 | Canaccord Genuity | Maintains | Buy | $42.00 → $46.00 |
| 2026-06-26 | Jefferies | Upgrade | Hold → Buy | $27.00 → $60.00 |
| 2026-06-11 | Canaccord Genuity | Maintains | Buy | $42.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 2.1% below the 50-day MA ($23.85).
- bullish: Price vs 200-day MA: Trading 5.8% above the 200-day MA ($22.05).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.34) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($7.49) and high ($32.90).
TNGX Price Chart
Loading chart for TNGX…
Fundamentals
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.